格列本脲预防缺血性卒中患者脑水肿和出血性转化
陈红艳;王红军
【期刊名称】《国际脑血管病杂志》 【年(卷),期】2015(000)005
【摘要】Cerebral edema and hemorrhagic transformation(HT) are the common complications of ischemic stroke. Ischemic cerebral edema is the primary cause of death in patients w ith large infarction. The sulfonylurea receptor 1 (Sur1) transient receptor potential M4 (Trpm4) channel plays an important role in focal cerebral ischemia. Both animal experiment and clinical studies have show n that the Sur1 selective inhibitor glibenclamide provides neuroprotection for ischemic stroke, including infarct volume reduction and improvement of neurological function, especial y in attenuating cerebral edema and reducing the incidence of HT. This article review s the advances in research on glibenclamide for the prevention of cerebral edema and HT in patients w
ith
ischemic
stroke.%
脑
水
肿
和
出
血
性
转
化
（hemorrhagictransformation,HT）是缺血性卒中的常见并发症。缺血性脑水肿是大面积脑梗死患者死亡的主要原因。磺脲类受体1（sulfonylurea receptor 1, Sur1）-瞬时受体电位通道M4型（transient receptor potential melastatin 4, Trpm4）通道在局灶性脑缺血中起着重要作用。动物实验和临床研究均显示，Sur1选择性抑制剂格列本脲可为缺血性卒中提供神经保护，包括缩小梗死体积和改善神经功能，特别是减轻脑水肿和降低HT 发生率。文章对
格列本脲预防缺血性卒中患者脑水肿和出血性转化
